Farletuzumab binds FRα on target cells and engages effector functions via its Fc, inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to lysis of FRα-positive cells; it also undergoes receptor-mediated internalization (used for ADC delivery).